Novo Nordisk AS

NVO

Company Profile

  • Business description

    With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the world's leading provider of diabetes care products. Based in Denmark, the company manufactures and markets a variety of human and modern insulins for patients with diabetes, as well as injectable and oral GLP-1 therapies, across its obesity and diabetes care segment. Novo also has a rare disease segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

  • Contact

    Novo Alle 1
    Bagsvaerd2880
    DNK

    T: +45 44448888

    E: [email protected]

    https://www.novonordisk.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - General

    Fiscal Year End

    31 December 2026

    Employees

    69,500

Novo Nordisk AS News & Analysis

stocks

2 companies poised to capitalize on the rise of GLP-1 drugs

Why Pfizer and Roche look like top choices for investors in the war to tip the scales.
markets

December 2025 US stock market outlook: Where we see investment opportunities

Heading into year-end, Santa Claus Rally or AI exhaustion?
stocks

3 ‘buy the dip’ candidates with wide moats

Does recent share price weakness spell opportunity in these three high-quality companies?

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,712.90123.70-1.40%
CAC 408,080.7466.09-0.81%
DAX 4025,463.81272.43-1.06%
Dow JONES (US)49,097.061,101.11-2.19%
FTSE 10010,452.6898.49-0.93%
HKSE22,841.62453.13-1.95%
NASDAQ23,879.20550.69-2.25%
Nikkei 22559,444.21419.930.71%
NZX 50 Index14,143.53103.72-0.73%
S&P 5007,175.83147.80-2.02%
S&P/ASX 2008,610.30120.10-1.38%
SSE Composite Index3,577.6210.21-0.28%

Market Movers